Business
IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea
Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agreement with Korea's GC Cell to introduce the CAR-T therapy "Fucaso" (Equecabtagene Autoleucel) to the South Korean market for the treatment of multiple myeloma. This partnership aims to provide a new therapeutic option for Korean patients with multiple myeloma, and GC Cell plans to sequentially pursue domestic regulatory approval and commercialization of Fucaso.
About this update from Gc Cell Corporation
[{"type":"list","items":[{"val":[{"type":"text","content":"Potential new treatment option for multiple myeloma patients in Korea.","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded patient access through competitive pricing.","length":52,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":122,"olType":false},{"type":"text","content":"SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agreement with Korea's GC Cell to introduce the CAR-T therapy "Fucaso" (Equecabtagene Autoleucel) to the South Korean market for the treatment of multiple myeloma. This partnership aims to provide a new therapeutic option for Korean patients with multiple myeloma, and GC Cell plans to sequentially pursue domestic regulatory approval and commercialization of Fucaso.","length":557,"tagName":"p"},{"type":"image","alt":"Signing ceremony photo: From left, Sungyong Won, Co-CEO of GC Cell, and Jinhua Zhang, Founder, Chairman, and CEO of IASO Bio","displaySize":"","headline":null,"caption":"Signing ceremony photo: From left, Sungyong Won, Co-CEO of GC Cell, and Jinhua Zhang, Founder, Chairman, and CEO of IASO Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":300,"url":"https://media.zenfs.com/en/prnewswire.com/28a5dfd4a31f14e5c92cf3b14f5d7c7b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MsAEl0gtH1fM9O.oygab7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUyOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/28a5dfd4a31f14e5c92cf3b14f5d7c7b","width":400,"height":300}},"href":"https://mma.prnewswire.com/media/2808113/Signing_ceremony_photo_From_left_Sungyong_Won_Co_CEO_GC_Cell.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Multiple myeloma is an incurable form of blood cancer with a high risk of relapse, most commonly affecting older adults. In South Korea, the number of multiple myeloma patients has been increasing annually due to an aging population. Many patients eventually develop resistance or refractoriness to existing treatments, limiting their effective options. While some combination therapies have recently become reimbursable — improving the initial treatment landscape — patients in fourth-line and later stages still face a critical lack of viab...